Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer

22 Nov 2013

Abstract excerpt

BACKGROUND: A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause. METHODS: A DNA methylation microarray was used to identify epigenetic differences in oxaliplatin-sensitive and -resistant colorectal cancer cells. The candidate gene SRBC was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Colorectal Cancer Treatments and Studies
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24273214
DOI: 10.1093/jnci/djt322

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal CancerPMID 24273214Read ↗

Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins.Semantic proximity Read ↗

Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cellsSemantic proximity Read ↗

Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian CancerSemantic proximity Read ↗

Integrated chromatin and transcriptomic profiling of patient-derived colon cancer organoids identifies personalized drug targets to overcome oxaliplatin resistanceSemantic proximity Read ↗

Gene signatures associated with drug resistance to irinotecan and oxaliplatin predict a poor prognosis in patients with colorectal cancerSemantic proximity Read ↗

Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecanSemantic proximity Read ↗

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell LinesSemantic proximity Read ↗

Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolutionSemantic proximity Read ↗

Functional Genomics Reveals Diverse Cellular Processes That Modulate Tumor Cell Response to OxaliplatinSemantic proximity Read ↗

High expression of microRNA‐625‐3p is associated with poor response to first‐line oxaliplatin based treatment of metastatic colorectal cancerSemantic proximity Read ↗

The cellular pharmacology of oxaliplatin resistanceSemantic proximity Read ↗

Modelling oxaliplatin resistance in colorectal cancer reveals a <i>SERPINE1</i> -based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtypeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.